vs

Side-by-side financial comparison of Generation Bio Co. (GBIO) and Laser Photonics Corp (LASE). Click either name above to swap in a different company.

Generation Bio Co. is the larger business by last-quarter revenue ($1.6M vs $919.3K, roughly 1.7× Laser Photonics Corp). Generation Bio Co. runs the higher net margin — -346.3% vs -506.4%, a 160.1% gap on every dollar of revenue. On growth, Laser Photonics Corp posted the faster year-over-year revenue change (28.3% vs -78.9%). Over the past eight quarters, Laser Photonics Corp's revenue compounded faster (-3.9% CAGR vs -25.6%).

Generation Bio Co. is a clinical-stage biotechnology firm focused on developing innovative non-viral gene therapies for both rare and common genetic diseases. Its core pipeline targets liver and retina disease indications, operates primarily in the U.S. market, and aims to deliver potential one-time curative treatments to patients with unmet medical needs.

IPG Photonics Corporation is a manufacturer of fiber lasers. IPG Photonics developed and commercialized optical fiber lasers, which are used in a variety of applications including materials processing, medical applications and telecommunications. IPG has manufacturing facilities in the United States, Germany, Russia and Italy.

GBIO vs LASE — Head-to-Head

Bigger by revenue
GBIO
GBIO
1.7× larger
GBIO
$1.6M
$919.3K
LASE
Growing faster (revenue YoY)
LASE
LASE
+107.2% gap
LASE
28.3%
-78.9%
GBIO
Higher net margin
GBIO
GBIO
160.1% more per $
GBIO
-346.3%
-506.4%
LASE
Faster 2-yr revenue CAGR
LASE
LASE
Annualised
LASE
-3.9%
-25.6%
GBIO

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
GBIO
GBIO
LASE
LASE
Revenue
$1.6M
$919.3K
Net Profit
$-5.5M
$-4.7M
Gross Margin
-20.1%
Operating Margin
-420.8%
-350.0%
Net Margin
-346.3%
-506.4%
Revenue YoY
-78.9%
28.3%
Net Profit YoY
64.0%
-186.5%
EPS (diluted)
$-0.82
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GBIO
GBIO
LASE
LASE
Q3 25
$1.6M
$919.3K
Q2 25
$765.0K
$2.6M
Q1 25
$8.7M
$2.3M
Q4 24
$4.2M
$1.3M
Q3 24
$7.6M
$716.7K
Q2 24
$4.1M
$623.4K
Q1 24
$4.1M
$743.0K
Q4 23
$2.9M
$994.6K
Net Profit
GBIO
GBIO
LASE
LASE
Q3 25
$-5.5M
$-4.7M
Q2 25
$-20.9M
$-1.8M
Q1 25
$-14.8M
$-1.7M
Q4 24
$-21.4M
$586.4K
Q3 24
$-15.3M
$-1.6M
Q2 24
$-20.4M
$-934.3K
Q1 24
$-74.5M
$-545.7K
Q4 23
$-35.2M
$-486.6K
Gross Margin
GBIO
GBIO
LASE
LASE
Q3 25
-20.1%
Q2 25
53.5%
Q1 25
49.8%
Q4 24
13.3%
Q3 24
85.0%
Q2 24
50.6%
Q1 24
51.9%
Q4 23
84.5%
Operating Margin
GBIO
GBIO
LASE
LASE
Q3 25
-420.8%
-350.0%
Q2 25
-2995.6%
-37.0%
Q1 25
-190.4%
-68.7%
Q4 24
-562.6%
-255.1%
Q3 24
-236.7%
-238.0%
Q2 24
-569.8%
-149.4%
Q1 24
-1912.6%
-73.8%
Q4 23
-1335.0%
-88.4%
Net Margin
GBIO
GBIO
LASE
LASE
Q3 25
-346.3%
-506.4%
Q2 25
-2735.0%
-68.3%
Q1 25
-169.7%
-73.4%
Q4 24
-510.6%
45.7%
Q3 24
-202.7%
-226.8%
Q2 24
-499.4%
-149.9%
Q1 24
-1836.4%
-73.4%
Q4 23
-1222.6%
-48.9%
EPS (diluted)
GBIO
GBIO
LASE
LASE
Q3 25
$-0.82
$-0.27
Q2 25
$-3.12
$-0.12
Q1 25
$-0.22
$-0.12
Q4 24
$4.50
$0.06
Q3 24
$-2.29
$-0.13
Q2 24
$-3.07
$-0.09
Q1 24
$-1.12
$-0.06
Q4 23
$-0.53
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GBIO
GBIO
LASE
LASE
Cash + ST InvestmentsLiquidity on hand
$89.6M
$3.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$50.6M
$4.1M
Total Assets
$121.9M
$17.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GBIO
GBIO
LASE
LASE
Q3 25
$89.6M
$3.6M
Q2 25
$141.4M
$78.5K
Q1 25
$157.6M
$179.1K
Q4 24
$185.2M
$533.9K
Q3 24
$184.8M
$2.1M
Q2 24
$216.9M
$2.7M
Q1 24
$219.3M
$5.2M
Q4 23
$264.4M
$6.2M
Stockholders' Equity
GBIO
GBIO
LASE
LASE
Q3 25
$50.6M
$4.1M
Q2 25
$54.1M
$4.3M
Q1 25
$73.3M
$6.8M
Q4 24
$86.2M
$10.2M
Q3 24
$104.4M
$9.7M
Q2 24
$115.4M
$10.3M
Q1 24
$132.0M
$12.4M
Q4 23
$203.1M
$13.9M
Total Assets
GBIO
GBIO
LASE
LASE
Q3 25
$121.9M
$17.5M
Q2 25
$179.4M
$14.9M
Q1 25
$201.3M
$16.0M
Q4 24
$231.2M
$17.2M
Q3 24
$248.8M
$10.6M
Q2 24
$265.3M
$11.1M
Q1 24
$285.9M
$13.6M
Q4 23
$374.8M
$15.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GBIO
GBIO
LASE
LASE
Operating Cash FlowLast quarter
$-52.7M
$763.1K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GBIO
GBIO
LASE
LASE
Q3 25
$-52.7M
$763.1K
Q2 25
$-16.8M
$-1.0M
Q1 25
$-28.4M
$-1.2M
Q4 24
$-15.8M
$-6.5M
Q3 24
$-19.5M
$632.7K
Q2 24
$-21.5M
$-2.4M
Q1 24
$-31.7M
$-866.3K
Q4 23
$-25.0M
$-2.0M
Free Cash Flow
GBIO
GBIO
LASE
LASE
Q3 25
Q2 25
$-17.3M
Q1 25
$-28.6M
Q4 24
$-16.2M
Q3 24
$-19.6M
$589.6K
Q2 24
$-21.5M
$-2.4M
Q1 24
$-33.6M
$-1.0M
Q4 23
$-29.6M
FCF Margin
GBIO
GBIO
LASE
LASE
Q3 25
Q2 25
-2259.7%
Q1 25
-327.9%
Q4 24
-385.9%
Q3 24
-260.0%
82.3%
Q2 24
-526.7%
-388.0%
Q1 24
-828.2%
-136.9%
Q4 23
-1027.0%
Capex Intensity
GBIO
GBIO
LASE
LASE
Q3 25
0.0%
Q2 25
60.0%
Q1 25
2.8%
Q4 24
9.0%
Q3 24
1.2%
6.0%
Q2 24
0.3%
5.1%
Q1 24
47.3%
20.3%
Q4 23
159.1%
Cash Conversion
GBIO
GBIO
LASE
LASE
Q3 25
Q2 25
Q1 25
Q4 24
-11.11×
Q3 24
Q2 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons